Suppr超能文献

浸润性上尿路尿路上皮癌联合器官保留治疗的疗效

Efficacy of combined organ-sparing management of invasive upper urinary tract urothelial carcinoma.

作者信息

Pikul Maksym V, Stakhovsky Eduard O

机构信息

Department of Plastic and Reconstructive Oncological Urology, National Cancer Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine.

出版信息

Cent European J Urol. 2023;76(2):162-166. doi: 10.5173/ceju.2023.019. Epub 2023 May 5.

Abstract

INTRODUCTION

The study aimed to evaluate the objective response level to neoadjuvant platinum-based chemotherapy and tumour complexity reduction in patients with invasive upper tract urothelial cancer (UTUC), and to estimate the functional and oncological outcomes of the combined organ-sparing approach compared to radical nephroureterectomy.

MATERIAL AND METHODS

This prospective, non-randomised cohort study was conducted by the National Cancer Institute of Ukraine. Patients with invasive UTUC were enrolled between October 2016 and January 2021. Patients were allocated to one of two cohorts depending on the estimated glomerular filtration rate (eGFR) of the affected kidney. In cases where eGFR was preserved, neoadjuvant chemotherapy with an organ-sparing approach was used; all other cases proceeded directly to radical nephroureterectomy.

RESULTS

A total of 64 patients (32 in each cohort) with invasive UTUC were enrolled. Both groups were comparable in terms of age, sex, T stage, maximal tumour size, eGFR, Eastern Cooperation Oncology Group (ECOG) performance status, body mass Index (BMI), and haemoglobin level. After four cycles of chemotherapy, there were no cases of progressive disease, stable disease [16 (50%), partial response; 12 (38%); and complete response, 4 (12%)]. The average maximal tumour size decreased by 2.3 cm. Prior to surgical treatment, total GFR according to scintigraphy did not statistically differ in both groups (р = 0.13). However, 3 months after surgery patients who underwent the organ-sparing approach had a better total eGFR (р = 0.0039), which was probably owing to the preserved kidney function (18.9 +5.1 mL/min). Better 2-year recurrence-free survival was also observed in the organ-sparing management group (85% vs 72%, log-rank test; p = 0.03).

CONCLUSIONS

Neoadjuvant systemic therapy reduces the surgical complexity of invasive UTUC without influencing the safety profile. The gemcitabine/cisplatin regimen leads to high regression rates among invasive UTUC, which could result in an organ-sparing approach in selected cases. Kidney function preservation remains a key parameter that can increase the possibility of effective systemic treatment.

摘要

引言

本研究旨在评估浸润性上尿路尿路上皮癌(UTUC)患者对新辅助铂类化疗的客观缓解水平以及肿瘤复杂性的降低情况,并估计与根治性肾输尿管切除术相比,联合保留器官方法的功能和肿瘤学结局。

材料与方法

本前瞻性、非随机队列研究由乌克兰国家癌症研究所开展。2016年10月至2021年1月期间纳入浸润性UTUC患者。根据患侧肾脏的估计肾小球滤过率(eGFR)将患者分配至两个队列之一。若eGFR保留,则采用新辅助化疗并结合保留器官的方法;所有其他病例直接进行根治性肾输尿管切除术。

结果

共纳入64例浸润性UTUC患者(每个队列32例)。两组在年龄、性别、T分期、最大肿瘤大小、eGFR、东部肿瘤协作组(ECOG)体能状态、体重指数(BMI)和血红蛋白水平方面具有可比性。化疗四个周期后,无疾病进展病例,疾病稳定[16例(50%),部分缓解;12例(38%)];完全缓解4例(12%)。平均最大肿瘤大小减小了2.3厘米。手术治疗前,两组根据闪烁扫描法测得的总肾小球滤过率无统计学差异(р = 0.13)。然而,术后3个月,采用保留器官方法的患者总eGFR更佳(р = 0.0039),这可能归因于保留的肾功能(18.9 +5.1毫升/分钟)。保留器官治疗组的2年无复发生存率也更高(85%对72%,对数秩检验;р = 0.03)。

结论

新辅助全身治疗可降低浸润性UTUC的手术复杂性,且不影响安全性。吉西他滨/顺铂方案在浸润性UTUC中导致高缓解率,这可能使部分病例能够采用保留器官的方法。肾功能保留仍然是一个关键参数,可增加有效全身治疗的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e610/10357825/22899932fedf/CEJU-76-172-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验